CORRECTION article

Front. Pharmacol., 02 September 2021

Sec. Pharmacology of Anti-Cancer Drugs

Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.753231

Corrigendum: NLRP3 Overexpression Associated With Poor Prognosis and Presented as an Effective Therapeutic Target in Osteosarcoma

  • 1. Department of Rehabilitation, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

  • 2. Department of Orthopedics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

  • 3. Fujian Orthopedics Research Institution, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

  • 4. Department of Nephrology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China

  • 5. Department of Orthopedics, The People’s Hospital of Jiangmen City, Southern Medical University, Jiangmen, China

  • 6. Department of Nursing, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

In the original article, there was a mistake in Figure 3 as published. In the process of rearranging our published articles, we found a problem by accident that the tubulin blots in Figure 3B were mistakenly uploaded. The corrected Figure 3 appears below.

FIGURE 3

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

osteosarcoma, prognosis, NLRP3, CY-09, lentivirus

Citation

Huang Z, Chen H, Wang S, Wei H, Wang X, Shen R, Wang Y, Lin R and Lin J (2021) Corrigendum: NLRP3 Overexpression Associated With Poor Prognosis and Presented as an Effective Therapeutic Target in Osteosarcoma. Front. Pharmacol. 12:753231. doi: 10.3389/fphar.2021.753231

Received

04 August 2021

Accepted

18 August 2021

Published

02 September 2021

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

12 - 2021

Updates

Copyright

*Correspondence: Jianhua Lin,

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics